ArticleCancer science2014
Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells.
Article in Cancer science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Digital spatial profiling identifies features of primary and locoregional metastatic vasculature in triple negative breast cancer.Clinical & experimental metastasis · 2026Article
- Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning.Journal of cellular and molecular medicine · 2024Article
- Identification of a distinct tumor endothelial cell-related gene expression signature associated with patient prognosis and immunotherapy response in multiple cancers.Journal of cancer research and clinical oncology · 2023Article
- Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance.Frontiers in physiology · 2023Review
- Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.Molecular cancer · 2022Article
- Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.Cancer science · 2022Article
- A Potential Diagnostic and Prognostic Biomarker TMEM176B and Its Relationship With Immune Infiltration in Skin Cutaneous Melanoma.Frontiers in cell and developmental biology · 2022Article
- TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer.Cells · 2021Article
- High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.Oncology reports · 2020Article
- Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.Clinical and experimental immunology · 2020Review
- Tumor Endothelial Heterogeneity in Cancer Progression.Cancers · 2019Review
- Development of Immortalized Human Tumor Endothelial Cells from Renal Cancer.International journal of molecular sciences · 2019Article
- Combination curcumin and (-)-epigallocatechin-3-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway.Oncogenesis · 2017Article
- Tumor endothelial cells accelerate tumor metastasis.Cancer science · 2017Review
- ROS enhance angiogenic properties via regulation of NRF2 in tumor endothelial cells.Oncotarget · 2017Article
- Phosphoproteomics Reveals Regulatory T Cell-Mediated DEF6 Dephosphorylation That Affects Cytokine Expression in Human Conventional T Cells.Frontiers in immunology · 2017Article
- Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.Advances in experimental medicine and biology · 2017Review
- DEF6 expression in ovarian carcinoma correlates with poor patient survival.Diagnostic pathology · 2016Article
- Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.The American journal of pathology · 2016Article
- RORγt+ cells selectively express redundant cation channels linked to the Golgi apparatus.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting tumor angiogenesis is an established strategy for cancer therapy. Because angiogenesis is not limited to pathological conditions such as cancer, molecular markers that can distinguish between physiological and pathological angiogenesis are required to develop more effective and safer approaches for cancer treatment. To identify such molecules, we determined the gene expression profiles of murine tumor endothelial cells (mTEC) and murine normal endothelial cells using DNA microarray analysis followed by quantitative reverse transcription-polymerase chain reaction analysis. We identified 131 genes that were differentially upregulated in mTEC. Functional analysis using siRNA-mediated gene silencing revealed five novel tumor endothelial cell markers that were involved in the proliferation or migration of mTEC. The expression of DEF6 and TMEM176B was upregulated in tumor vessels of human renal cell carcinoma specimens, suggesting that they are potential targets for antiangiogenic intervention for renal cell carcinoma. Comparative gene expression analysis revealed molecular differences between tumor endothelial cells and normal endothelial cells and identified novel tumor endothelial cell markers that may be exploited to target tumor angiogenesis for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.